Overcoming matrix barriers for enhanced immune infiltration using siRNA-coated metal-organic frameworks
Source abstract
Abstract
The extracellular matrix (ECM) of solid tumor constitutes a formidable physical barrier that impedes immune cell infiltration, contributing to immunotherapy resistance. Breast cancer, particularly triple-negative breast cancer (TNBC), is characterized by a collagen-rich tumor microenvironment, which is associated with T cell exclusion and poor therapeutic outcomes. Discoidin domain receptor 2 (DDR2) and integrins, key ECM regulatory receptors on cancer cells, play pivotal role in maintaining this barrier. In this study, we developed a dual-receptor-targeted strategy using metal-organic frameworks (MOFs) to deliver DDR2-specific siRNA (siDDR2) and ITGAV-specific siRNA (siITGAV) to disrupt the ECM barrier. siDDR2 modulates immune infiltration by regulating collagen-cell interactions, while siITGAV suppresses TGF-β1 activation. The MOF@siDDR2+siITGAV complex significantly reduced collagen deposition, enhanced CD8+ T cell infiltration, and downregulated programmed cell death ligand 1 (PD-L1) expression in TNBC. Consequently, this approach markedly inhibited tumor growth. Our findings demonstrate that dual-receptor-targeted MOF-based nanocarriers (MOF@siDDR2+siITGAV) can effectively reprogram the tumor ECM to enhance immune cell access, offering a promising prospect for synergistic cancer immunotherapy. STATEMENT OF SIGNIFICANCE: A dual-receptor-targeted MOF nanocarrier is developed to improve immune accessibility in tumors. Concurrent blockade of DDR2 and ITGAV effectively decreases collagen deposition, increases CD8+ T cell infiltration, and suppresses PD-L1 expression. Modulating the mechanical properties of the extracellular matrix (ECM) to enhance immune accessibility offers an innovative strategy for cancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Development of immunotherapy combination strategies in cancer[J]10.1158/2159-8290.CD-20-1209 ↗
2. Immunological hallmarks of stromal cells in the tumour microenvironment[J]10.1038/nri3902 ↗
3. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion[J]10.1038/s41586-021-04057-2 ↗
4. Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation[J]10.1038/s41467-021-26352-2 ↗
5. Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma[J]10.1016/j.addr.2021.02.019 ↗
6. Targeting the microenvironment in solid tumors[J]10.1016/j.ctrv.2018.02.004 ↗
7. ECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models[J]10.1016/j.jconrel.2023.02.001 ↗
8. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy[J]10.1126/sciadv.aav2437 ↗
9. Integrin αvβ6-TGFβ-SOX4 pathway drives immune evasion in triple-negative breast cancer[J]10.1016/j.ccell.2020.12.001 ↗
10. Every step of the way: integrins in cancer progression and metastasis[J]10.1038/s41568-018-0038-z ↗
11. Integrins in cancer: biological implications and therapeutic opportunities[J]10.1038/nrc2748 ↗
12. Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment[J]10.1038/s41580-019-0134-2 ↗
13. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance[J]10.1016/j.ccell.2019.01.007 ↗
14. Recent trends in cancer therapy: a review on the current state of gene delivery[J]10.1016/j.lfs.2021.119087 ↗
15. Small interfering RNA for cancer treatment: overcoming hurdles in delivery[J]10.1016/j.apsb.2020.10.005 ↗
16. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy[J]10.3390/molecules25112692 ↗
17. Therapeutic siRNA: state of the art[J]10.1038/s41392-020-0207-x ↗
18. Delivery materials for siRNA therapeutics[J]10.1038/nmat3765 ↗
19. Rekindling RNAi therapy: materials design requirements for In vivo siRNA delivery[J]10.1002/adma.201903637 ↗
20. Lipid nanoparticle technology for clinical translation of siRNA therapeutics[J]10.1021/acs.accounts.9b00368 ↗
21. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo[J]10.1002/anie.201203263 ↗
22. siRNA delivery systems for cancer treatment[J]10.1016/j.addr.2009.04.018 ↗
23. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles[J]10.1016/j.jconrel.2018.03.012 ↗
24. Multifunctional metal-organic framework heterostructures for enhanced cancer therapy[J]10.1039/D0CS00178C ↗
25. Metal-organic framework nanoparticles[J]10.1002/adma.201800202 ↗
26. Environment-responsive lipid/siRNA nanoparticles for cancer therapy[J]10.1002/adhm.202001294 ↗
27. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape[J]10.1038/nbt.2612 ↗
28. Calcium enabled remote loading of a weak acid into pH-sensitive liposomes and augmented cytosolic delivery to cancer cells via the Proton sponge effect[J]10.1007/s11095-022-03206-0 ↗
29. Assembly and biological functions of metal-biomolecule network nanoparticles formed by metal-phosphonate coordination[J]10.1126/sciadv.ads9542 ↗
30. Mechanisms of cellular uptake and endosomal escape of calcium-siRNA nanocomplexes[J]10.1016/j.ijpharm.2016.10.009 ↗
31. Metal-phenolic coatings as a platform to trigger endosomal escape of nanoparticles[J]10.1021/acsnano.9b05521 ↗
32. Histidine-based coordinative polymers for efficient intracellular protein delivery via enhanced protein binding, cellular uptake, and endosomal escape[J]10.1039/D2BM01541B ↗
33. Metal-organic frameworks for stimuli-responsive drug delivery[J]10.1016/j.biomaterials.2019.119619 ↗
34. A review of recent developments of metal-organic frameworks as combined biomedical platforms over the past decade[J]10.1016/j.cis.2023.102908 ↗
35. A fluorescence nanoplatform for the determination of hydrogen peroxide and adenosine triphosphate via tuning of the peroxidase-like activity of CuO nanoparticle decorated UiO-66[J]10.1007/s00604-022-05170-3 ↗
36. Adenosine metabolism: emerging concepts for cancer therapy[J]10.1016/j.ccell.2019.10.007 ↗
37. ATP-triggered anticancer drug delivery[J]10.1038/ncomms4364 ↗
38. A DNA/DMXAA/metal-organic framework activator of innate immunity for boosting anticancer immunity[J]
39. Independent drug action in combination therapy: implications for precision oncology[J]10.1158/2159-8290.CD-21-0212 ↗
40. Targeting FAK in anticancer combination therapies[J]10.1038/s41568-021-00340-6 ↗
41. Integrin-mediated mechanotransduction[J]10.1083/jcb.201609037 ↗
42. Regulation of chondrocyte differentiation by the actin cytoskeleton and adhesive interactions[J]10.1002/jcp.21110 ↗
43. TGF-β: the master regulator of fibrosis[J]10.1038/nrneph.2016.48 ↗
44. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]10.1186/s12943-022-01569-x ↗
45. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression[J]10.1038/s41563-020-00849-5 ↗
46. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy[J]10.1016/j.jconrel.2012.04.045 ↗
47. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics[J]10.1038/s41571-022-00601-9 ↗
48. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors[J]10.1172/JCI45817 ↗
49. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers[J]10.1172/JCI96313 ↗
50. Profiling tumor infiltrating immune cells with CIBERSORT[J]10.1007/978-1-4939-7493-1_12 ↗
51. Zirconium: biomedical and nephrological applications[J]10.1097/MAT.0b013e3181e73f20 ↗
52. Immune modulatory properties of collagen in cancer[J]10.3389/fimmu.2021.791453 ↗
53. Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1[J]10.1016/j.molimm.2011.09.006 ↗
54. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors[J]10.1021/acsnano.9b02395 ↗